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Statement of Disclosure
• I have no relevant financial relationships that 
would be considered a conflict of interest for the 
purposes of this program.
• This presentation will include discussion of non-
FDA approved (off-label) medication use.
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Objectives
• Describe the advances in hepatitis C treatment 
and drug management challenges
• Describer the hepatitis C monitoring program 
implemented to contain costs and to promote 
optimal member care
• List the outcomes of the hepatitis C monitoring 
program as well as the lessons learned
• Identify current management strategies for novel 
hepatitis C agents
• Hepatitis C virus (HCV) infection is the most 
common chronic bloodborne infection in the United 
States
• At least 3.2 million people chronically infected
o 75% are unaware they have infection
• Treatment goal is HCV eradication, preventing 
complications and liver related deaths
• AASLD/IDSA/IAS-USA recommend combination 
treatment with oral direct-acting antivirals for most 
patients with chronic HCV infection
Hepatitis C Overview
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Advances in the Treatment of Hepatitis C
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BOC=boceprevir, IFN=interferon, LDV=ledipasvir, PEG=peginterferon alfa, 
RBV=ribavirin, r=ritonavir, SMV=simeprevir, SOF=sofosbuvir, SVR=sustained 
virologic response, TVR=telaprevir
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Drug Management Challenges
• High cost of therapy ($63,000 to $300,720)
• As many as 200,000 Massachusetts residents 
may be infected with HCV
• Several treatment regimens are available which 
vary in duration, tolerability, and cost per cure
• Prioritizing members based on liver disease stage
• Suboptimal medication adherence may lead to 
treatment failure and drug resistance
• Medication waste if member never starts or does 
not complete treatment
• Promote cost-effective regimen use through 
telephonic prescriber outreach on prior 
authorization (PA) requests
• Promote medication adherence through refill 
reminders using pharmacy claims data
• Identify members with undetectable HCV viral load 
12 weeks post-therapy completion (SVR12) by 
conducting prescriber outreach
Medication Monitoring Program Objectives
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Monitoring Program Process Overview
Guideline Development
Prior Authorization
Extensive Internal Training
Requested Regimen 
Tracking
Prescriber Outreach to Discuss 
Cost-effective Therapies
Medication Adherence 
Tracking
Specialist Input
Medication Adherence 
Outreach to Prescribers
Prescriber Outreach 
to Gather Outcomes
Team Approach
Outcomes Analysis
Reporting
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Key Collaborators
• Clinical Pharmacy Services
o Operational and clinical pharmacist
o Pharmacy associates, supervisors, appeals
• MassHealth Office of Clinical Affairs
• Infectious Diseases specialist and Drug Utilization 
Review Board input
• Massachusetts Behavioral Health Partnership (MBHP)
• Prescribers and their representatives (nurses, medical 
assistants)
• Medicaid managed care organizations
The tracking log began in December 2013
• Member and prescriber demographics
• Disease-specific parameters, such as:
o Baseline HCV viral load
o HCV genotype
o Liver disease stage
o Prior therapy with response
• Medication fill dates
• Viral load 12 weeks after treatment 
completion
Methods: Tracking Log
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• Clinical pharmacists contact prescriber 
o Discuss use of alternative regimens
o Discuss appropriateness of therapy deferral
o Close or extend PAs, if clinically appropriate
• Pharmacy associates contact prescriber
o Inform of refill being due 
o Inquire if virological cure has been achieved
• Approved members with substance use 
disorders are referred to case management
Methods: Interventions
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Results: Study Population (N=500)
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PA approval for sofosbuvir-containing 
regimen from 12/18/13 to 09/30/14
Promote appropriate 
medication use
• Improve medication adherence
• Reduce drug waste
• Prevent therapy interruptions
Telephonic outreach to prescriber
&
Results: Study Population (N=500)
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Interventions to promote 
appropriate medication use 
N=121 (24.2% of total)
PA approval for pharmacist-
recommended regimen 
N=34 (6.8% of total)
Approval  of more 
cost-effective regimens 
N=25 (5.0% of total)
Approval of regimens that were 
not necessarily more cost-
effective N=9 (1.8% of total)
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Pharmacist Interventions: Examples
Promoting Optimal Hepatitis C Regimen Selection
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Telephonic Interventions by Pharmacists 
to Discuss Alternative Regimens
Cost-effectiveness considerations
• HCV genotype 1, naïve or PEG/RBV relapsers
o SOF/RBV x 24 weeks  SOF+PEG/RBV x 12 weeks
or SOF/SMV x 12 weeks (PEG ineligible)
• HCV genotype 2, treatment-experienced with cirrhosis
o SOF/RBV x 12 weeks  SOF+PEG/RBV x 12 weeks
• HCV genotype 3
o SOF/RBV x 24 weeks  SOF+PEG/RBV x 12 weeks
HCV=hepatitis C virus, PEG=peginterferon, RBV=ribavirin, SMV=simeprevir
SOF=sofosbuvir
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Telephonic Interventions by Pharmacists 
to Discuss Alternative Regimens
Lack of efficacy data
• HCV genotype 1, prior protease inhibitor exposure
o SOF/SMV x 12 weeks  SOF+PEG/RBV x 12 weeks
Safety concerns
• HCV genotype 1, decompensated liver disease
o SOF/SMV x 12 weeks  SOF/RBV for up to 48 weeks
Delaying therapy consideration
• HCV genotype 1, early fibrosis (F0-F2)
o XXXXX  SOF/LDV or 3-D combination*
HCV=hepatitis C virus, PEG=peginterferon, RBV=ribavirin, SMV=simeprevir, SOF=sofosbuvir
*ombitasvir/paritaprevir/ritonavir; dasabuvir ± RBV
Interventions Resulting in Regimen Change
February 27, 2015
HCV Genotype 1 Infection PA Approvals
Requested 
Regimen
Recommended
Regimen
# of 
Members Member Characteristics
SOF/RBV SOF/SMV±RBV 14* PEG ineligible
SOF+PEG/RBV SOF/SMV 5 PEG/RBV nonresponder
SOF/SMV SOF+PEG/RBV 4* Treatment-naïve
SOF/RBV SOF+PEG/RBV 2* PEG eligible
SOF/SMV SOF+RBV 2 Prior PI exposure and PEG ineligibility
SOF/SMV SOF+PEG/RBV 1 Prior PI exposure
SOF/SMV SOF+RBV 1 Liver decompensation
PEG=peginterferon alfa, PI=protease inhibitor, RBV=ribavirin, SMV=simeprevir, SOF=sofosbuvir 
*A total of 19 members who completed treatment with the more cost-effective regimen were included in the cost-
avoidance analysis. 
Interventions Resulting in Regimen Change
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HCV Genotype 3 Infection PA Approvals
Requested 
Regimen
Recommended
Regimen
# of 
Members Member Characteristics
SOF+RBV SOF+PEG/RBV 3* Treatment-naïve, no cirrhosis
SOF+RBV SOF+PEG/RBV 1* Treatment-naïve, cirrhosis
SOF+RBV SOF+PEG/RBV 1* Treatment-experienced, cirrhosis
PEG=peginterferon alfa, RBV=ribavirin, SOF=sofosbuvir 
*A total of 19 members who completed treatment with the more cost-effective regimen were included in the cost-
avoidance analysis. 
Results: Study Population (N=500)
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Promoting medication adherence, drug waste reduction, 
and preventing interruptions in therapy 
Prescriber personnel contacted 
to inform of refill due 
N=278 (55.6% of total)
≥26 days from last sofosbuvir or 
simeprevir claim 
N=418 (83.6% of total)
Subsequent paid claim
N=217 (43.4% of total)
PAs were closed early 
N=50 (10.0% of total)
Filled same day, late 
start, loss of coverage 
N=140 (28.0% of total)
PAs extended 
N=11 (2.2% of total)
Interventions to Improve Medication Adherence
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Clinical Pharmacist Interventions Resulting in PA Closure
Rationale for 
Intervention
Number of Members
SOF/RBV SOF+PEG/RBV SOF/SMV±RBV Total
Therapy deferral 9 3 3 15
Adverse event 9 5 0 14
Nonadherence 7 1 2 10
Loss to follow-up 3 1 2 6
Loss of coverage 3 0 0 3
Change in 
treatment plan 1 0 1 2
Total 32 10 8 50
PA=prior authorization, PEG=peginterferon alfa, RBV=ribavirin, SMV=simeprevir, SOF=sofosbuvir
Interventions to Improve Medication Adherence
February 27, 2015
Clinical Pharmacist Interventions Resulting in PA Extension
Rationale for 
Intervention
Number of Members
SOF/RBV SOF+PEG/RBV SOF/SMV±RBV Total
Late start 2 5 4 11
Total (closed or 
extended PAs) 34 15 12 61
PA=prior authorization, PEG=peginterferon alfa, RBV=ribavirin, SMV=simeprevir, SOF=sofosbuvir
• A total of 17 members with comorbid substance use 
disorders have been referred for enrollment into a case 
management program.
Interventions to Promote Cost-Effective Medication Use
• 19 members completed therapy with more cost-effective, 
pharmacist-recommended regimen
o Estimated cost avoidance: $884K to $1.7M*
 11 members achieved SVR12
 3 had undetectable viral load at the end of treatment
 5 - data is pending
Interventions to Reduce Drug Waste
• Pharmacies for two of 51 members, for whom PAs have 
already been closed early, have attempted to submit a 
claim, which were rejected at the point-of-sale
o Estimated drug waste cost-avoidance: $59K
Summary of Cost-Avoidance Estimates
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*Cost-avoidance was calculated as the difference in cost (or cost/cure) between the pharmacist-
recommended regimen and the regimen originally requested by the prescriber.
• A Hepatitis C monitoring program has proven to be 
successful in this Medicaid program
o Opportunity for optimal, cost-effective regimen selection
o Refill reminders and member referral to case 
management may promote medication adherence
o Potential for drug waste reduction from identifying 
members who discontinue therapy
o Ability to identify members who achieve virologic cure
• High cost of therapy, high prevalence of chronic 
infections, and availability of several regimens support an 
ongoing monitoring program
Summary
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Lessons Learned
• Proactively develop a management strategy for 
the new agents before FDA approval
• Continuous quality improvement
o Timely revisions to internal guidelines
o Staff training and retraining
o Tracking outcomes
• Cooperation at all levels
o Operational, clinical, prescriber and pharmacy
• Serve as a resource to prescribers
o Refill reminders outreach
o Online materials
FDA=Food and Drug Administration
February 27, 2015
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Current and Future Management Strategies
Appropriate Member Screening, Regimen Selection, 
Treatment Monitoring, Outcome Collection
February 27, 2015
Novel Hepatitis C Agents
• New agents are changing hepatitis C treatment
o Harvoni® (ledipasvir/sofosbuvir)
o Viekira Pak™ (ombitasvir/paritaprevir/ritonavir; 
dasabuvir)
• Offer comparable efficacy in many patient populations
• Additional pill burden, side effects, drug interaction, 
contraindications, and differences in cost should be 
considered
• Several commercial payers have already negotiated 
favorable pricing with drug manufacturers
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Current and Future Management Strategies
• Regimen selection and duration
o HCV genotype and subtype
o Compensated vs decompensated cirrhosis
o Prior treatment history and response
o Drug interactions and contraindications
• Promoting optimal adherence
o Enrollment into case management
o Refill reminder phone calls
• Futility rules
• Fibrosis: controversial
o “Who to treat and when”
• Selection of a preferred regimen
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Trends in Utilization for 2014
*Excludes claims where state Medicaid is the secondary payor
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Total Pharmacy Spend on Hepatitis C Agents
*Total spend excludes claims where state Medicaid is the secondary payor
AASLD=American Association for the Study of Liver Diseases, FDA=Food 
and Drug Administration, IDSA=Infectious Diseases Society of America
Viekira Pak® (ombitasvir, paritaprevir and ritonavir; dasabuvir)
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Treatment Completion and Cure Rates
December 18, 2013 – December 31, 2014
Treatment completed 
based on pharmacy 
claims data
Due for 12-week 
post-therapy 
completion viral load 
SVR* Detectable  
viral load after 
treatment
Number  
of 
members
380 286 138 31
SVR=sustained virologic response; includes members with undetectable viral load at least 11 weeks after 
treatment completion
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Conclusion
• New agents have dramatically improved cure 
rates in the treatment of hepatitis C
• High treatment costs necessitate careful 
screening for appropriate candidates, regimen 
selection, and adherence monitoring
• Hepatitis C monitoring program has shown 
promise in reducing costs and improving member 
care
• Lessons learned could be applicable to other 
medically complex disease states
Questions/Comments?
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Thank you!
February 27, 2015
References
• AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating 
hepatitis C. http://www.hcvguidelines.org. Accessed January 18, 2015. 
• Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the 
Study of Liver Diseases. Diagnosis, Management and treatment of hepatitis C; 
An Update. 2009. Hepatology 2009; 49(4):1-40.
• Massachusetts Department of Public Health. Clinical Advisory: Routine 
Screening for Hepatitis C. http://www.mass.gov/eohhs/docs/dph/aids/hcv-
clinical-advisory.pdf. Accessed January 30, 2015
• Sovaldi® (sofosbuvir) product eDossier. December 20, 2013. Version 
3.1. Gilead Sciences. Accessed via secure log in to the 
AMCP eDossier System (https://amcp.edossiers.com) on December 20, 2013.
• Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study 
of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. 
Hepatology. 2004 Apr;39(4):1147-71.
• US FDA. FDA Antiviral Drugs Advisory Committee Meeting October 25, 2013: 
Background Package for NDA 204671 Sofosbuvir (GS-7977). 2013 Oct [cited 
2015 Jan 18]. Available from:   
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Ant
iviralDrugsAdvisoryCommittee/ucm371875.htm.
